Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

Inclusion Criteria: * Male patients aged over 50 * Clinically diagnosed benign prostate hyperplasia(BPH) * 8 ≤ IPSS ≤ 30 * 4 ml/sec ≤ Q max ≤ 15 ml/sec * minimum voided volume ≥ 125 ml * Post voided residual volume ≤ 250 * Volunteer who singed on informed consent documents Exclusion Criteria: * Past history of surgical procedure experience related to BPH * Past history of taking 5-alpha reductase inhibitor(5-ARI) within 6 months before screening, or for more than 12 months regardless of the point of time * Past history of taking alpha blocker within 2 weeks before screening * Past history of acute urinary retention within 3 months before screening * Serum PSA ≥ 10 ng/ml (but, in the case of 4 ng/ml ≤ PSA \< 10 ng/ml, the patients can be included only if prostate cancer is excluded by prostate biopsy) * Anatomical abnormalities of lower urinary tracts(urethrostenosis, diverticulosis, bladder neck contracture) * Clinical status that affects voiding other than BPH(neurogenic bladder, Chronic Prostatitis/Chronic Pelvic Pain Syndrome, urinary infection, etc.) * Unstable and significant medical condition including below * Unstable angina pectoris, myocardial infarction, cerebrovascular disease within 6 months before screening * Past history of malignant tumor including skin basal cell carcinoma within 5 years before screening * Medically uncontrollable diabetes mellitus, peptic ulcer disease * Severe hepatic diseases * Past history of renal failure or renal disease (serum creatinine \> 1.4mg/dl) * Condition expected serious adverse event due to the investigational drug * Other conditions considered not eligible for the trial upon investigator's judgement